For & Against

What's Next

Centene's next confirmed catalyst is the first-quarter earnings call on April 28, 2026. The decision point is not revenue growth by itself; it is whether the first repriced quarter shows HBR moving toward the 90.9%-91.7% FY2026 guide while Marketplace paid claims and Medicaid trend stop worsening.

No Results

Centene's IR calendar lists Q1 earnings for April 28 at 8:30 a.m. EDT, and the company said results will be released around 6:00 a.m. EDT. Third-party previews bracket the Q1 EPS debate at roughly $1.85 to $2.18, with revenue near $47.5B and an HBR print near 89.3% in the lower-EPS preview, but the cleaner test is whether management can defend the full-year adjusted EPS floor above $3.00 without pushing the HBR repair farther out. CMS also gives two sector-specific dates that matter here: June 1 for CY2027 Part D bid/formulary submissions and July 31 for proposed individual-market rate filings.

For / Against / My View

For

**HBR is the fulcrum.** Centene does not need heroic revenue growth; it needs repriced claims math on an enormous premium base. Every 100 bps HBR improvement is worth roughly $1.7B pre-tax, and 2026 guidance already targets consolidated HBR down from 91.9% to a 90.9%-91.7% range. (Business)

Evidence: Business: FY2025 HBR was 91.9%, FY2026 guide is 90.9%-91.7%, and a 100 bps move equals roughly $1.7B of pre-tax pressure or relief.

**Cash absorbs the reset.** This is a damaged earnings story, not a liquidity story: FY2025 operating cash flow recovered to $5.1B, capex is structurally below 1% of revenue, and cash of $17.9B slightly exceeds total debt of $17.5B. (Numbers)

Evidence: Numbers: FY2025 operating cash flow was $5.1B; capex usually runs under 1% of revenue; cash was $17.9B versus $17.5B of total debt.

**Focus meets accountability.** The conglomerate overhang has been cut away, and the pay structure punished the miss: 2023-2025 performance RSUs vested at 0%, the 2025 cash incentive paid 71.6% of target, and the CEO bought stock after the dislocation. (Story; People)

Evidence: Story: non-core assets were sold, impaired, or moved toward divestiture and adjusted SG&A improved from 8.5% in FY2024 to 7.4% in FY2025; People: CEO Sarah London bought 19,230 shares for about $490K in August 2025.

Bull Price Target

$75

Timeline: 24 months. Primary catalyst: A post-repricing quarter with consolidated HBR below 91% and Marketplace commentary confirming paid-claims normalization. (Numbers; Business)

Against

**HBR eats the spread.** Centene has no margin cushion: fixed premiums meet claims data, acuity shifts, and state rates after enrollment, leaving medical-cost drift to absorb the spread. A 91%+ HBR means the 2026 EPS floor depends on rate catch-up, not operating leverage.

Evidence: Numbers: FY2025 HBR was 91.9%, FY2026 HBR guide is 90.9%-91.7%, and each 100 bps moves roughly $2B of operating earnings; Business: medical costs/HBR were 91.9% of the 2025 premium dollar, SG&A was 7.4%, and underwriting slack was 0.7%.

**Scale worsened underwriting.** Marketplace scale became adverse selection: Ambetter membership grew, Commercial gross margin collapsed, and the 2026 plan shrinks revenue to repair pricing. The moat claim fails when the leader must shrink to earn.

Evidence: Story: Ambetter reached 5.5M Marketplace members in FY2025, Commercial gross margin fell $2.6B despite 26% membership growth, and 2026 Marketplace revenue is guided down about $8B; Business: scale helps contracts, but a bad rate year overwhelms back-office scale.

**Guidance lost credit.** Management's valuation-relevant promises are not bankable after the 2025 guide collapse and Medicaid HBR miss. The board and incentives add no owner backstop, with low insider ownership and expensive pay after the impairment year.

Evidence: Story: April FY2025 adjusted EPS guidance above $7.25 became $2.08 actual after July withdrawal, and Medicaid HBR sits at 93.7% for FY2025 and the 2026 guide; People: insiders own 0.37%, CEO SCT pay was $19.5M, and GAAP results included a $6.7B goodwill impairment.

Bear Downside Target

$28

Trigger: Next reported HBR above 92% plus Marketplace commentary that paid claims remain worse than priced; Numbers says another quarter above 92% makes the base case too generous.

The Tensions

1. HBR: operating leverage or no margin cushion?

Bull says the recovery does not need heroic growth because every 100 bps of HBR improvement is worth roughly $1.7B pre-tax on a huge premium base. Bear says the same 91%+ HBR leaves almost no underwriting slack, so the 2026 EPS floor depends on rate catch-up rather than operating leverage. Both cite FY2025 HBR of 91.9%, FY2026 HBR guidance of 90.9%-91.7%, and a roughly $1.7B-$2.0B earnings swing for every 100 bps of HBR. This resolves on the next two earnings reports: consolidated HBR below 91% with Marketplace paid-claims normalization supports Bull; HBR above 92% with worse-than-priced Marketplace morbidity supports Bear.

My View

I'd lean cautious here. The Against side weighs a little more because the HBR tension is not just a valuation debate; the full-year guide asks investors to accept a 90.9%-91.7% HBR path after 2025 printed 91.9% and management missed the old EPS story badly. The bull case has a real path if repricing moves HBR below 91% with clean cash flow and normalized Marketplace paid claims, but the burden of proof sits with the company. I would wait for April 28 and the late-July quarter to show either sub-91% consolidated HBR or a credible bridge to it. A confirmed HBR below 91% with Marketplace paid claims normalizing and no receivable or cash deterioration would flip the view.